Tivic Health Systems, Inc.

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) issued 250 Series B Non-Voting Convertible Preferred Shares and warrants to purchase 156,026 common shares to 3i, LP, for an aggregate purchase price of $250,000. This transaction, completed on June 17, 2026, is part of a previously announced Securities Purchase Agreement from April 29, 2025, which was later assigned to 3i. The securities were issued under an exemption from registration.

Tivic Health Systems, Inc. held its 2026 Annual Meeting of Stockholders on May 28, 2026, where several key proposals were approved. Stockholders ratified an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 2,581,608. Additionally, Dean Zikria was elected as a Class II director, and Rosenberg Rich Baker Berman, P.A. was ratified as the independent registered public accounting firm. Stockholders also approved the issuance of common stock related to the conversion of Series C Preferred Stock and warrants, as well as the conversion of a Senior Secured Convertible Note and warrant to 3i, LP.

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) reported a net loss of $6.2 million for Q1 2026, significantly wider than the $1.5 million loss in Q1 2025. The company's cash and cash equivalents decreased to $7.2 million, and it used $5.0 million in cash from operations, raising substantial doubt about its ability to continue as a going concern. Additionally, Valion Bio received a Nasdaq notification for non-compliance with the minimum bid price requirement. The company also completed the wind-down of its ClearUP business.

Valion Bio (formerly Tivic Health Systems, Inc.) reported a net loss of $6.2 million for Q1 2026, compared to $1.5 million in Q1 2025. Operating expenses increased to $5.6 million from $1.4 million, primarily due to the acquisition of Velocity Bioworks and corporate rebranding costs. The company completed its corporate transformation, changing its name to Valion Bio, Inc. and ticker to VBIO, while advancing its Entolimod platform, increasing government engagement, and integrating its CDMO subsidiary, Velocity Bioworks.

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, effective May 4, 2026. Ms. Lackey brings over 18 years of legal and corporate experience, including executive and legal leadership roles at biotechnology companies like Alaunos Therapeutics and Kuur Therapeutics. Her compensation package includes an annual base salary of $321,000, eligibility for an annual incentive bonus up to 35% of her base salary, and an option to purchase 45,000 shares of common stock. This appointment is strategic as Valion Bio advances Entolimod™ and scales its CDMO subsidiary, Velocity Bioworks.

Valion Bio, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026. Stockholders will vote on several key proposals, including the election of a Class II director and an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 2,581,608. Additionally, the company seeks approval for multiple common stock issuances related to convertible preferred stock, warrants, and an equity line of credit, all in accordance with Nasdaq Listing Rule 5635(d).

Tivic Health Systems, Inc. announced a corporate name change to Valion Bio, Inc., effective April 28, 2026. Concurrently, the company's common stock will cease trading under the ticker symbol 'TIVC' and begin trading under the new ticker symbol 'VBIO' on The Nasdaq Capital Market LLC, also effective April 28, 2026. The name change did not require a shareholder vote and does not affect shareholder rights.